Format

Send to

Choose Destination
Alzheimers Dement. 2018 Jan;14(1):81-103. doi: 10.1016/j.jalz.2017.10.002. Epub 2017 Nov 8.

Blood DNA methylation as a potential biomarker of dementia: A systematic review.

Author information

1
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Disease Epigenetics, Murdoch Children's Research Institute, The University of Melbourne, Parkville, Victoria, Australia.
2
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia.
3
Disease Epigenetics, Murdoch Children's Research Institute, The University of Melbourne, Parkville, Victoria, Australia.
4
Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Victoria, Australia; Disease Epigenetics, Murdoch Children's Research Institute, The University of Melbourne, Parkville, Victoria, Australia; INSERM, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France. Electronic address: joanne.ryan@monash.edu.

Abstract

Dementia is a major public health issue with rising prevalence rates, but many individuals remain undiagnosed. Accurate and timely diagnosis is key for the optimal targeting of interventions. A noninvasive, easily measurable peripheral biomarker would have greatest utility in population-wide diagnostic screening. Epigenetics, including DNA methylation, is implicated in dementia; however, it is unclear whether epigenetic changes can be detected in peripheral tissue. This study aimed to systematically review the evidence for an association between dementia and peripheral DNA methylation. Forty-eight studies that measured DNA methylation in peripheral blood were identified, and 67% reported significant associations with dementia. However, most studies were underpowered and limited by their case-control design. We emphasize the need for future longitudinal studies on large well-characterized populations, measuring epigenetic patterns in asymptomatic individuals. A biomarker detectable in the preclinical stages of the disease would have the greatest utility in future intervention and treatment trials.

KEYWORDS:

Alzheimer's disease; Biomarker; Blood; DNA methylation; Dementia; Epigenetics; Peripheral

PMID:
29127806
DOI:
10.1016/j.jalz.2017.10.002

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center